Biopharmaceutical company Citius Oncology Inc (Nasdaq: CTOR), a subsidiary of Citius Pharmaceuticals Inc (Nasdaq: CTXR), on Wednesday reported continued commercial progress for LYMPHIR, with the number of new institutional accounts ordering the cancer treatment increasing 78% quarter over quarter for the period ended 30 June 2026.

LYMPHIR is now available at 42 institutions, including academic oncology centres, National Comprehensive Cancer Network institutions and community infusion centres. Vials ordered by institutions through wholesalers rose 31% during the quarter, while the company expects to add more than 20 further institutions in the current quarter and is targeting formulary inclusion at 100 priority institutions by year-end.

The company said LYMPHIR has secured near-universal payer coverage, supporting broader market access alongside continued formulary adoption. Management estimates the initial market for the treatment of relapsed or refractory cutaneous T-cell lymphoma exceeds USD400m.